Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study

Conclusion
This study confirms the favourable, long-term benefit-to-risk profile of the FAc implant in eyes with cDMO, with an additional benefit in patients when this therapy is administered earlier.

Source: British Journal of Ophthalmology - September 21, 2023 Category: Opthalmology Authors: Khoramnia, R., Peto, T., Koch, F., Taylor, S. R., Castro de Sousa, J. P., Hill, L., Bailey, C., Chakravarthy, U., On behalf of the ILUVIEN Registry Safety Study (IRISS) Investigators Group, Hamilton, Guzaliya, Geeta, Ramesh, Haralabos, Simon, Saad, Konsta Tags: Open access Original articles - Clinical science Source Type: research